omalizumab
UkraineDrugs containing this active substance
-
The drug is used as add-on therapy to achieve better control in the following conditions: severe persistent allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Form: powder for injection solution
Active substance Dosage omalizumab 75 mg ATC: R03DX05
Manufacturer: Novartis Pharma Stein AG
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Form: powder for injection solution
Active substance Dosage omalizumab 150 mg ATC: R03DX05
Manufacturer: Novartis Pharma Stein AG
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Form: solution for injection
Active substance Dosage omalizumab 75 mg/0.5 ml ATC: R03DX05
Manufacturer: Novartis Pharma GmbH (Batch release)
-
The drug is used as add-on therapy for the treatment of severe allergic asthma (in adults and children from 6 years of age), chronic rhinosinusitis with nasal polyps (in adults), and chronic spontaneous urticaria (in adults and adolescents from 12 years of age).
Form: solution for injection
Active substance Dosage omalizumab 150 mg/ml ATC: R03DX05
Manufacturer: Novartis Pharma GmbH (Batch release)